Upstate Active Clinical Trials

Study Title:

Roche WN39658: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH
PRODROMAL TO MILD ALZHEIMER’S DISEASE (GRADUATE II)

What is the purpose of the study?

The purpose of this study is to evaluate the effects, good or bad, of gantenerumab versus placebo (an inactive substance that looks like gantenerumab) on you and your memory problems.

Upstate Institutional Review Board (IRB) Number:

1118966

Study/Protocol ID:

WN39658

Study Phase:

Phase III

Patient Age Group:

Adults

Principal Investigator:

Sharon A Brangman

ClinicalTrials.Gov ID:

NCT03443973

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Linda L Spillett, CCRP
Phone: 315-464-9017
Email: spilletl@upstate.edu

Return to Previous Page || Search Again

Top